Mündliche Prüfung »   Ponatinib hydrochloride (HCl) API

Ponatinib hydrochloride (HCl) API, a tyrosine kinase inhibitor, has emerged as a powerful tool in treating certain types of leukemia. However, its journey since FDA approval has been marked by both promise and controversy. While clinical trials demonstrated its efficacy, real-world evidence (RWE) is crucial for understanding its effectiveness and safety in everyday clinical practice.
https://www.qingmupharm.com/pharmaceutical-compositions-and-process-of-ponatinib-hcl-api